- Home
- TRT vs GNLX Comparison
TRT vs GNLX Comparison
Compare TRT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRT | GNLX |
|---|---|---|
| Founded | 1958 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 133.0M |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TRT | GNLX |
|---|---|---|
| Price | $11.68 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | ★ 858.8K | 166.1K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $32,462,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $600.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.42 | $2.29 |
| 52 Week High | $21.38 | $8.54 |
Technical Indicators
Market Signals| Indicator | TRT | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 46.20 |
| Support Level | $9.93 | $2.62 |
| Resistance Level | $14.78 | $3.03 |
| Average True Range (ATR) | 1.58 | 0.17 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 30.90 | 40.91 |
Price Performance
Historical ComparisonAbout TRT Trio-Tech International
Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.